Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2026): Yao J+, Oncology Jul, Online ahead of print [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
Systolic dysfunction / ejection fraction reduced
- (2020): Du N+, Anticancer Agents Med Chem Dec, Online ahead of print [REVIEW]
